• Autonomix Medical disclosed positive preclinical study results on July 24, 2026 for its renal nerve sensing platform.
• Results were presented in the announcement, not flagged for a future conference or publication.
• Study showed the system could detect renal nerve activity, localize targets, then confirm activity changes following ablation.
• Readout supports continued development of physiology-guided renal denervation, aimed at improving procedural precision versus landmark-based approaches.
• Company plans additional preclinical work, then future clinical studies to evaluate the approach in patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240847PRIMZONEFULLFEED9767498) on July 24, 2026, and is solely responsible for the information contained therein.